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Abstract  39 
While NOD-SCID IL2Rγ-/- (NSG) xenograft mice are currently the most frequently used 40 
model to study human leukemia in vivo, the absence of a human niche severely 41 
hampers faithful recapitulation of the disease. We used NSG mice in which ceramic 42 
scaffolds seeded with human mesenchymal stromal cells were implanted to generate a 43 
human bone marrow (huBM-sc)-like niche. We observed that, in contrast to the murine 44 
bone marrow (mBM) niche, expression of BCR-ABL or MLL-AF9 was sufficient to 45 
induce both primary AML and ALL. Stemness was preserved within the human niches 46 
as demonstrated by serial transplantation assays. Efficient engraftment of AML MLL-47 
AF9 and blast-crisis CML patient cells was also observed, whereby the immature blast-48 
like phenotype was maintained in the huBM-sc niche, but to a much lesser extent in 49 
mBM niches. We compared transcriptomes of leukemias derived from mBM niches 50 
versus leukemias from huBM-like scaffold-based niches, which revealed striking 51 
differences in expression of genes associated with hypoxia, mitochondria and 52 
metabolism. Finally, we utilized the huBM-sc MLL-AF9 B-ALL model to evaluate the 53 
efficacy of the I-BET151 inhibitor in vivo. In conclusion, we have established human 54 
niche models in which the myeloid and lymphoid features of BCR-ABL+ and MLL-AF9+ 55 
leukemias can be studied in detail.  56 
 57 
  58 
 59 
 60 
 61 
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Introduction 62 
Establishing xenograft models is essential to study the molecular mechanisms involved 63 
in human leukemias aimed at improving treatment options. Currently, NOD-SCID IL2Rγ-64 
/- (NSG) xenograft models are considered as the gold standard for evaluating the 65 
engraftment of human hematological malignancies. However, despite being the most 66 
immune compromised mouse strain available allowing a more efficient and faster 67 
disease development compared to other NOD/SCID-related strains,1-3 also NSG mice 68 
are suboptimal since 30-40% of primary AML samples failed to engraft.4 Obviously, a 69 
human bone marrow (huBM) environment is lacking in these animals, and such a 70 
humanized niche might be essential to provide the optimum concentration of 71 
endogenous cytokines, chemokines and adhesion factors to allow efficient engraftment 72 
and maintenance of different leukemia clones. Indeed, engraftment of normal human 73 
CD34+ cells in NSG mice is lymphoid biased. Using retro/lentiviral systems to model 74 
human leukemias we frequently observe that while in vitro both myeloid and lymphoid 75 
transformation can be achieved upon expression of oncogenes such as MLL-AF9 or 76 
BCR-ABL/BMI1, in vivo transformation is strongly biased towards ALL.5,6 In patients the 77 
BCR-ABL p210 oncoprotein can give rise to both myeloid and lymphoid leukemias, and 78 
the same is true for MLL-AF9 in pediatric leukemia patients. Together, these 79 
observations suggest that a specific human microenvironment might be necessary for 80 
engraftment and maintenance of self-renewal of myeloid leukemic stem cells (LSCs). 81 
Since certain myeloid growth factors are often species-specific, the mouse niche does 82 
not suffice to provide the appropriate environment for human LSCs. 83 
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To develop in vivo models that more faithfully recapitulate human disease driven by the 84 
BCR-ABL p210 translocation and by MLL-AF9 we made use of a humanized niche NSG 85 
xenograft model in which ceramic scaffolds coated with human mesenchymal stromal 86 
cells (MSCs) were implanted in NSG mice where they developed into structures 87 
mimicking a human bone marrow microenvironment.7,8 Next, we studied the 88 
engraftment and initiation of CML by cord blood (CB) CD34+ cells transduced with BCR-89 
ABL with or without BMI1 (where indicated) or with MLL-AF9, as well as engraftment of 90 
primary CML and AML patient cells. Our data indicate that serially transplantable ALL 91 
and primary AML could be established in the humanized scaffold xenograft model. 92 
Differences between transcriptome profiles of BCR-ABL cells harvested from murine 93 
and human niches were analyzed, and thus we identified niche-specific BCR-ABL 94 
signatures. Ultimately, we also took advantage of the huBM-sc MLL-AF9 B-ALL model 95 
to evaluate the efficacy of I-BET151 inhibitor in vivo.  96 
 97 
Materials and Methods 98 
 99 
Establishment of the humanized scaffold niche xenograft model  100 
The ectopic bone model was established as described previously.7,8 Briefly, four hybrid 101 
scaffolds consisting of three 2–3mm biphasic calcium phosphate (BCP) particles loaded 102 
with human MSCs were implanted subcutaneously into 8 week old female NOD.Cγ-103 
Prkdcscid Il2rγtm1Wjl/SzJ (NSG) mice. Neonatal CB samples were obtained after 104 
informed consent from healthy full-term pregnancies from the obstetrics departments of 105 
the University Medical Center in Groningen (UMCG) and Martini Hospital Groningen. 106 
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CB CD34+ cells were isolated as described previously.6,9 500,000 non-sorted cells were 107 
directly injected into the scaffolds or i.v. as indicated during primary as well as 108 
secondary transplantations. CD45 engraftment was analyzed by timely bleeding 109 
procedures. 110 
 111 
Retroviral and lentiviral transductions  112 
The murine stem cell virus (MSCV)-BMI1-internal ribosomal entry site (IRES2)- 113 
enhanced green fluorescent protein (EGFP) and MSCV-BCR-ABL-IRES2-truncated 114 
nerve growth factor receptor (tNGFR) retroviral vectors were cloned into MiGR1 and 115 
MiNR1 as previously described.6 MLL-AF9 vectors were described previously.5,10 116 
Transductions of CB CD34+ cells were performed as described previously.6,9  117 
 118 
LTC-IC 119 
For the LTC-IC assays, newly transduced cells were sorted on MS5 stromal cells in 120 
limiting dilutions from 10 to 500 cells per well in 96-well plates as described previously.9 121 
After 5 weeks of culture, the wells containing cobblestone areas were scored, after 122 
which the medium from the wells was aspirated and replaced with methylcellulose-123 
containing cytokines. After an additional 2 weeks of culture, wells were scored as 124 
positive or negative to yield the LTC-IC frequency. Stem cell frequencies were 125 
calculated using L-Calc software (Stem Cell Technologies).  126 
 127 
Further Materials and methods are provided as supplemental information. 128 
 129 
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Results  130 
Murine versus human extrinsic cues dictate transformation potential in BCR-131 
ABL/BMI1 and MLL-AF9-induced leukemia in humanized xenograft models. 132 
We have evaluated human BCR-ABL, BCR-ABL/BMI1 and MLL-AF9-driven 133 
leukemogenesis in the murine BM niche using classical NSG xenotransplantation 134 
models, and compared that to leukemogenesis in the presence of a humanized bone 135 
marrow microenvironment. In line with what we observed previously,6 only cells 136 
expressing both BCR-ABL and BMI1 were able to generate CD34+/CD19+ B-ALL in the 137 
mouse bone marrow environment when injected intravenously (i.v.) into sublethally 138 
irradiated NSG mice (Figure 1a, c, d and Supplementary Table 1). Infiltration of double 139 
positive ALL cells was seen in spleen and liver (Supplementary Figure S1a-b) and no 140 
myeloid or erythroid cells expressing CD33, CD11b, CD15 or GPA were observed in 141 
leukemic mice.  142 
Next, we injected non-sorted CB CD34+ cells transduced with BCR-ABL and BMI1 143 
directly into a humanized model that is based on subcutaneous implantation of human 144 
BM-like scaffolds (huBM-sc), as described previously.7,8 In 11-21 weeks, 11 out of 13 145 
mice developed palpable tumors at the site of injection and data for all these 11 mice is 146 
summarized in Figure 1a, Supplementary Table 1, and Supplementary Figure S1c. In 147 
contrast to i.v. injected mice that all developed CD19+ B-ALL, in transcutaneous injected 148 
huBM-sc mice both CD19+ B-ALL phenotypes and CD19- AML phenotypes were 149 
observed (Figure 1c, 1d, Supplementary Table 1). When transduced cells were injected 150 
into empty scaffolds or scaffolds coated with MSCs that were irradiated with 30 Gy prior 151 
to implantation leukemia development was never observed. Migration of cells to the 152 
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murine BM was observed in 3 out of 11 huBM-sc mice, typically with a lineage 153 
phenotype resembling that of the leukemic cells in the huBM scaffolds (Supplementary 154 
Table 1). 155 
When freshly transduced CB MLL-AF9 cells were transplanted i.v. into NSG mice, a 156 
CD19+ lymphoid leukemia could be generated within 11-25 weeks, and again myeloid 157 
engraftment was difficult to achieve. In only about 10% of the cases, mixed-lineage 158 
leukemias were observed in which both CD19+ B-ALL and CD33+/CD19- myeloid clones 159 
were only observed, in line with previous observations.5,11 Upon direct injection of CB 160 
MLL-AF9 into huBM-sc mice, all animals developed a fatal leukemia with a latency of 161 
16-32 weeks. Although leukemia development was still biased towards CD19+ B-ALL, 162 
more mixed leukemias with both B-ALL and AML clones were observed within the 163 
humanized niche, and in one case AML without B-ALL clones was observed (Figure 1c-164 
d, Supplementary Table 1). Overall, leukemia development was slightly slower in the 165 
huBM-sc model compared to the muBM i.v. model (although the difference did not 166 
reach significance, Mantel-Cox test p=0.0678), possibly related to the observation that 167 
myeloid leukemias developed less fast compared to lymphoid B-ALLs. 168 
 169 
BCR-ABL can induce lymphoid and myeloid leukemia in a human niche 170 
xenotransplant model without exogenous BMI1.  171 
Within 11-21 weeks, 11 out of 13 mice developed tumors at the site of injection of non-172 
sorted BCR-ABL/BMI1-transduced cells in huBM-sc mice. Interestingly, 14 out of 18 173 
leukemic scaffolds contained BCR-ABL-single positive leukemias, which was never 174 
observed in the mouse BM niche in i.v. injected mice, while 4 out of 18 huBM-sc derived 175 
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leukemias both BCR-ABL single positive as well as BCR-ABL and BMI1 double positive 176 
clones were detected (Figure 1d, Supplementary Table 1). Apparently, in a humanized 177 
microenvironment co-expression of exogenous BMI1 was not required to induce BCR-178 
ABL-positive leukemia. 179 
Furthermore, the huBM-sc allowed for the development of a variety of phenotypes 180 
ranging from B-ALL with aberrant expression of myeloid markers, to more erythroid- and 181 
myeloid-biased leukemias, regardless of whether these were BCR-ABL single positive 182 
or BCR-ABL and BMI1 double positive clones. For example, huBM scaffold 3 of mouse 183 
m5 (Figure 2a-e) developed tumors that were white of color, were BCR-ABL single 184 
positive and expressed CD19 and CD38, while CD34, GPA and CD11b were not 185 
expressed (Figure 2a). CD33, CD36 and CD15 expression was also detected (Figure 186 
2a). Immunohistochemical analysis confirmed human bone formation in the scaffolds 187 
(Figure 2c, d, Supplementary Figure S2a). Infiltration of BCR-ABL single cells was 188 
observed in different organs like BM, spleen and liver and these cells showed a similar 189 
marker expression as the cells engrafted in the huBM-sc (Supplementary Figure 2b-d). 190 
MGG staining confirmed a lymphoblastic phenotype of these cells and hence we 191 
concluded that mice developed B-ALL with aberrant expression of certain myeloid 192 
antigens (Figure 2e). Similar results were obtained for other B-ALLs in mouse m5 huBM 193 
scaffold 2 and mouse m9 huBM scaffold 2 (Supplementary Table 1). 194 
In the huBM-sc mouse m1 the developing tumors were more compact and red (huBM 195 
scaffold 3) or green (huBM scaffolds 1 and 4) indicative of erythroid development and 196 
myeloperoxidase expression, respectively. These were CD19neg but did express 197 
intermediate to high levels of GPA and CD33, with the highest expression of GPA in 198 
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huBM scaffold 3 (Figure 2f). In addition, mice with both BCR-ABL single as well as 199 
BCR-ABL/BMI1 double positive leukemic clones were obtained (m10, Figure S2e). This 200 
mouse displayed an immature tumor phenotype as indicated by high expression of C-201 
KIT (CD117) and low expression of other myeloid markers. No differences in FACS 202 
phenotype were observed between BCR-ABL single and BCR-ABL/BMI1 double 203 
positive clones (Figure S2e).  204 
 205 
Increased incidence of myeloid leukemia observed in huBM-Sc MLL-AF9-induced 206 
models.  207 
Three out of the 4 scaffolds were injected with 3x105 unsorted CB CD34+ cells 208 
transduced with MLL-AF9 in a total of 8 huBM-scaffold mice. Palpable tumors 209 
developed in 19/24 injected scaffolds and also in 5 out of 8 of the non-injected scaffolds. 210 
Clearly, huBM-sc were sufficiently vascularized to allow migration of tumor cells from 211 
injected scaffolds to non-injected scaffolds, as well as to mouse compartments. LM-212 
PCRs were performed to study clonality (Supplementary Figure S3b-d). We observed 213 
that multiple co-existing clones and integration sites could be identified that were 214 
different in independent experiments. Furthermore, in mice in which one scaffold was 215 
the most dominant growing one (e.g. Sc2 in mouse 5, Supplementary Figure S3b) 216 
similar integrations sites were found in the human scaffold and the murine BM (e.g. the 217 
red integration site), but also that slight changes in clonality were observed as well (e.g. 218 
the yellow integrations site in BM and Sc2). In other cases where multiple scaffolds 219 
generated leukemias, different unique clones could engraft in individually injected 220 
scaffolds (Sc1 versus Sc3, indicated by different colors), whereby one clone that was 221 
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seen in the dominant clone in bone marrow (red clone) was also seen in the scaffolds. 222 
And finally, in a secondary transplantation experiment most but not all primary clones 223 
were seen in secondary leukemias grown in the scaffolds or BM (Supplementary Figure 224 
S3d, Sc2 in mouse 1 versus 2nd Sc1-3 and BM, red integration site), although some 225 
integration sites were only seen in one scaffold (Sc3, green integration site), and 226 
additional clones appeared upon 2nd transplantation as well (sc2-3, yellow integration 227 
site), which were most likely quiescent in the primary transplant. 228 
In 3/8 huBM-sc mice (m1-m3), exclusively CD19+ B-ALL was observed in the scaffolds, 229 
with phenotypes resembling those we previously observed in i.v. injected NSG mice 230 
without human niches (5,6 and Figure 3a-d, Supplementary Table 1). Within these mice, 231 
infiltration to mouse organs was observed as well, displaying phenotypes similar to 232 
those in the humanized scaffolds. Some mice displayed a somewhat more mature 233 
leukemic B-ALL phenotype with the presence of CD19+/CD20+ clones (data not shown). 234 
In 4 out of 8 huBM-sc mice (m4-m7) both B-ALL as well as myeloid CD19-/CD33+ 235 
clones were detected (Figure 3e, Supplementary Table 1, Supplementary Figure 3), and 236 
in one mouse (m8) one scaffold was completely lymphoid while another was completely 237 
myeloid. Within this myeloid clone, some co-expression of myeloid markers such as 238 
CD11b, CD15 and CD14 with CD33 was also detected, resembling the phenotype we 239 
observe in in vitro myeloid cultures as well as in patients, and the lymphoid and myeloid 240 
phenotypes were confirmed by MGG staining (Figure 3f-g).  241 
In total, and in contrast with murine niches, out of 24 engrafted scaffolds we observed 242 
co-existing myeloid and lymphoid clones in 9 cases (37.5%), and a complete myeloid 243 
clone in 1 case (4.1%) although this difference did not reach statistical significance 244 
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(p=0.0804). Taken together these data suggest that the ectopic human BM 245 
microenvironment provides a more permissive microenvironment to drive LSCs towards 246 
myeloid differentiation. 247 
 248 
Self-renewal is maintained within human niches as shown by serial 249 
transplantation, but remains lymphoid biased. 250 
In order to evaluate the self-renewal potential of BCR-ABL single positive leukemic 251 
clones we performed secondary transplantations. Cells harvested from huBM scaffold 3 252 
of mouse m5 were transplanted into 3 sub-lethally irradiated NSG mice carrying huBM 253 
scaffolds, such that 3 scaffolds were inoculated with 0.16x106 cells per scaffold, while 1 254 
scaffold was left uninjected (Figure S4a). Large tumors were observed in all 3 255 
secondary transplanted mice and within 6 weeks mice presented with overt leukemia 256 
(Figure 1a, d, S4b). All injected huBM scaffolds of all 3 secondary transplanted mice 257 
contained BCR-ABL single-positive cells. FACS analyses indicated that different clones 258 
had engrafted into individual scaffolds. Some scaffolds contained CD19, CD38 and 259 
CD33 positive cells comparable to their phenotype in primary mice, although expression 260 
of CD15 was lost (Figure S4c-e). huBM scaffold 2 from mouse m5.1 displayed multiple 261 
clones that varied in tNGFR expression, suggesting different levels of BCR-ABL 262 
expression in these clones. Clones with intermediate levels of BCR-ABL expression 263 
were positive for GPA while clones with the highest expression of BCR-ABL did not 264 
express GPA but in contrast expressed high levels of CD19 (Supplementary Figure S4f 265 
and data not shown). Infiltration of BCR-ABL single positive cells was also observed to 266 
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some extend in BM, spleen and liver, although chimerism levels were very low 267 
(Supplementary Table 1).  268 
To obtain further insight into the clonality of these different engrafting populations, we 269 
performed LM-PCR on cells harvested from primary as well as secondary huBM 270 
scaffolds. As shown in Figure S4g, multiple bands were observed suggesting the 271 
coexistence of multiple clones. The clone indicated by the red asterisk was detected in 272 
both the primary and all secondary transplanted animals. Furthermore, multiple different 273 
other integration sites were observed in secondary leukemic mice, indicative for 274 
oligoclonal disease. Since a number of these clones were not detected in the primary 275 
mouse these data suggest the presence of quiescent clones in the primary leukemic cell 276 
population that were activated upon serial transplantation.  277 
In order to assess the self renewal potential of CB MLL-AF9 leukemic cells generated in 278 
huBM-sc of primary recipients, we also performed secondary transplantation. 279 
CD19+/CD15+ lymphoid leukemic cells harvested from mouse m1 huBM-sc2 were 280 
transplanted into humanized NSG mice. Tumor formation was observed in all the 281 
injected scaffolds and FACS analyses displayed the same phenotype observed in the 282 
primary recipient, although expression of CD15+ was lost (Figure S4h). Infiltration of CB 283 
MLL-AF9 positive cells was also observed in BM, spleen and liver albeit the chimerism 284 
levels were lower in comparison to primary recipients (Supplementary Table 1). 285 
Furthermore, we performed a secondary transplantation using cells from m6 huBM-sc2 286 
that contained two distinct clones of CD33+ (78.3%) and CD19+ (~3%). Due to the small 287 
number of cells available, only a single secondary huBM-sc could be injected with 1x105 288 
unsorted cells. Tumor formation was observed in the injected scaffold and the mouse 289 
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was sacrificed upon signs of illness after 15 weeks. Despite the fact that the vast 290 
majority of injected cells were of myeloid origin, a CD19+/CD33- B-ALL developed in the 291 
scaffold, most likely arising from the small population of CD19+ cells in the primary 292 
recipient (Figure S4i), a feature we have observed more frequently. These results 293 
indicate that despite the presence of a human niche microenvironment, MLL-AF9-294 
induced transformation of neonatal CB CD34+ cells remain biased towards B-ALL. 295 
 296 
Molecular characterization of cells derived from the murine niche versus the 297 
human niche.  298 
Illumina microarray analysis was performed to study transcriptome differences between 299 
murine niche-derived and human niche-derived BCR-ABL positive positive cells. BCR-300 
ABL cells harvested from scaffolds from primary mice (1st huBM-sc), BCR-ABL cells 301 
harvested from scaffolds from secondary transplanted mice (2nd huBM-sc) as well as 302 
primary BCR-ABL/BMI1 cells harvested from murine BM and spleen (1st mBM/Spleen) 303 
were compared. 577 probesets were significantly upregulated in the huBM-sc derived 304 
leukemic cells compared to the mBM/Spleen-derived cells, while 458 probesets were 305 
downregulated (corrected p value<0.01 with Benjamini-Hochberg  multiple testing 306 
correction, >3 fold differentially expressed, Supplementary Table 2). These data indicate 307 
that significant differences existed in transcriptome signatures between leukemias that 308 
developed in the mBM versus huBM scaffold niches. The top differentially expressed 309 
genes are shown in the supervised cluster analysis in Figure 4a, indicating that the 1st 310 
huBM-sc sample clustered tightly together with the eight 2nd huBM-sc samples, while all 311 
three 1st mBM/Spleen samples clustered together, away from all huBM-sc samples.  312 
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Gene ontology (GO) analyses indicated that the huBM-sc overexpressed genes were 313 
significantly (FDR<1) enriched for processes such as apoptosis and mitochondrion. 314 
Genes upregulated in mBM-derived leukemias were significantly (FDR<1) enriched for 315 
GO terms methylation and histone core related genes (Figure 4b). GSEA analysis 316 
indicated that huBM scaffold-derived leukemias were enriched for MYC targets and 317 
hypoxia signatures, suggesting that BCR-ABL-positive cells derived from the humanized 318 
scaffold display differences in MYC dependency and hypoxic state as compared to 319 
mBM-derived leukemias (Figure 4c). A number of selected GO terms for genes 320 
upregulated in huBM scaffold-derived leukemias are shown in Figure 5d and 321 
Supplementary Figure S5. Interestingly, p57, and MYC were some of the significantly 322 
overexpressed secreted proteins in huBM scaffold-derived leukemias. Another 323 
interesting observation was that endogenous BMI1 was overexpressed in BCR-ABL 324 
positive cells derived from humanized scaffolds, possibly explaining why exogenously 325 
overexpressed BMI1 is not required as is the case for leukemias that develop in the 326 
murine BM niche. Illumina data were validated by independent Q-PCR analyses (Figure 327 
4e).  328 
 329 
Primary Blast Crisis (BC)-CML and AML-MLL-AF9 cells can induce a fatal myeloid 330 
leukemia within 16 weeks post transplantation in the huBM scaffold mouse model 331 
Next, cells from a blast crisis-chronic myeloid leukemia (BC-CML) primary patient were 332 
injected i.sc. in huBM scaffold mice (Figure 5a). We observed that all three injected 333 
mice developed tumors within 16 weeks post-transplantation. Tumors were well 334 
vascularized and greenish of color (Figure 5b), and were positive for huCD45 as well as 335 
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for myeloid markers like CD33, CD11b, CD14, and CD38 (Figure 5c). MGG staining 336 
clearly revealed the immature phenotype of scaffold-harvested cells as compared to 337 
murine BM-harvested cells (Figure 5d). Infiltration of myeloid cells was observed in 338 
mouse BM, spleen and liver (Supplementary Figure S6a). Cells in the mBM niche 339 
displayed a more differentiated phenotype in terms of a higher proportion of cells 340 
expressing the markers CD11b, CD14 and CD15 while a lower proportion of cells 341 
expressed CD34 (Figure 5c, S6a-c). In contrast, leukemic cells derived from the huBM 342 
scaffold more closely resembled the original patient and in particular CD34 percentages 343 
were quite comparable (Figure 5c, S6a-c). These FACS analyses were confirmed by 344 
immunohistochemistry (Supplementary Figure S6b).  345 
The self-renewing potential of cells harvested from the murine BM niche and those 346 
retrieved from the human niche in the huBM scaffolds was functionally studied in LTC-347 
IC assays. CD34+ and CD34- cells were sorted and plated in limiting dilution and were 348 
scored after 5 weeks. No cobblestone area forming cells (CAFCs) were detected at 349 
week 5 in CD34+ or CD34- isolated from murine BM harvested cells (Figure S6d), and 350 
only differentiated macrophages could be observed (data not shown). In contrast, 351 
CAFCs could readily be detected in cultures initiated with CD34+ cells isolated from the 352 
huBM scaffold harvested cells, with an LTC-IC frequency of 1 in 323 +/-115 (Figure 353 
S6d). Thus, these results suggest that self-renewal of LT BC-CML LSCs was 354 
maintained in the context of a humanized BM niche. Maintenance of self-renewal was 355 
also demonstrated in vivo by serial transplantation assays (Antonelli, Groen and 356 
Schuringa, to be submitted).  357 
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Finally, Q-PCR analyses was performed on BC-CML samples harvested from the 358 
mouse BM and human scaffold niches, and similar as observed in our BCR-ABL 359 
retroviral overexpression models, a significantly increased level of endogenous BMI1 360 
was observed in cells derived from human scaffolds (Supplementary Figure S6e). 361 
Lastly, we also injected primary MLL-AF9 AML patient material into huBM-sc of a NSG 362 
mouse. Two scaffolds were injected with 1x106   cells each. While we did not detect any 363 
CD45+ chimerism in the blood during the course of the experiment, we sacrificed the 364 
mouse 20 weeks after transplantation upon palpation of tumor growth on one of the 365 
scaffolds (Figure 5e). Cells retrieved from the huBM-sc3 displayed a myeloid phenotype 366 
with expression of CD33, CD11b and CD15 (Figure 5f), which was further confirmed by 367 
MGG staining of cytospins (Figure 5g). No human cells could be detected in mouse 368 
organs such as spleen, liver and or BM by FACS analyses (Figure 5f), and the spleen 369 
size was not enlarged (weight: 0.12g).  370 
 371 
Intrascaffold in vivo treatment with IBET151 372 
We next evaluated whether the huBM-sc model could also be used for drug testing. In 373 
our in vitro CB MLL-AF9 myeloid and lymphoid MS5 co-culture system we observed 374 
that, upon inhibition of BRD3/4 binding to acetylated histones with the small molecule I-375 
BET15112,13 proliferation was severely impaired (data not shown). Here, we assessed 376 
the therapeutic potential of I-BET151 in vivo in our huBM-sc B-ALL CB MLL-AF9 377 
xenograft model. 5x105 cells harvested from a primary B-ALL MLL-AF9 generated in 378 
huBM-sc mice were injected into 3 huBM scaffolds of secondary recipients, while the 379 
fourth scaffold was left uninjected. Four weeks after injection of the cells, we performed 380 
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daily i.sc. injections of the inhibitor for a total of 23 days. One control group (n=5) was 381 
injected with a solution of PBS and DMSO 1%, one group (n=3) with I-BET151 500 µM 382 
and another group (n=5) with I-BET151 5mM. Tumor volume size of each scaffold was 383 
measured during the experiment every 3 days, allowing us to monitor the progression of 384 
the disease in time. All mice were sacrificed at the same time at day 54 after injection. 385 
Mice treated with 5 mM I-BET151 displayed a significant reduction in tumor volume (~2 386 
fold, p<0.0001). Accordingly, also the cell number of the cells harvested from the tumors 387 
was significantly different (for 500 µM group p=0.04, for 5 mM group p=0.01) (Figure 6a-388 
d). No significant differences were found in spleen weight or blood and BM chimerism. 389 
Together, these data indicate that I-BET151 treatment significantly delays lymphoid 390 
leukemia progression in vivo, but is not sufficient for a complete eradication of the 391 
leukemic cells, at least not in this experimental setting.  392 
 393 
Discussion  394 
Despite many advantages of various xenotransplantation mouse models for human 395 
leukemias that have been developed till date, faithful recapitulation of myeloid 396 
phenotypes and efficient maintenance of long-term self-renewal of LSCs has remained 397 
challenging. One of the fundamental drawbacks of currently available mouse models to 398 
study human leukemias is the absence of a human microenvironment that would 399 
potentially provide species-specific cytokines, growth factors and adhesion molecules 400 
that are essential for self-renewal and myelopoiesis. Here we used our previously 401 
developed humanized mouse model that provides a human BM-like scaffold-based 402 
19 
(huBM-sc) microenvironment7,8 in which human myeloid and lymphoid leukemias can be 403 
studied in detail. 404 
Various retro/lentiviral models have been established to model human myeloid and 405 
lymphoid leukemias, and while in vitro BCR-ABL or MLL-AF9 oncogenes (either alone 406 
or in combination with other hits) could induce transformation along myeloid or lymphoid 407 
lineages, in vivo transformation was always heavily lymphoid biased and in vivo myeloid 408 
transformation has been much more difficult to achieve in NOD-SCID based xenograft 409 
models, including the NSG mice.5,6,11,14 Furthermore, a significant number of primary 410 
AML samples does not engraft in the NSG mouse model4, again pinpointing to the 411 
notion that a niche that allows self-renewal of myeloid (malignant) clones is not provided 412 
for in the NSG mouse. Over the past years, xenograft leukemia models have already 413 
been significantly improved, and advantages and disadvantages of various humanized 414 
mouse models have recently been nicely reviewed.3,15 NOD/SCID-3/GM/SF mice 415 
engineered to produce human IL3, GM-CSF and SF16,17 and NOD-SCID IL2Rγ-/- (NSG) 416 
mice expressing human IL3, GM-CSF and SF (NS-SGM3)18 have been generated 417 
which enhanced engraftability of primary human AML samples, as well as others19-23 418 
including MISTRG mice expressing  M-CSF,  IL3, GM-CSF,  TPO and SIRPα.19  Even 419 
MDS patient samples or MDS-derived cell lines were reported to engraft making use of 420 
human cytokine mice.24,25 These models are clearly useful tools, although other human 421 
niche-specific factors might still be missing.  422 
We made use of a humanized mouse xenograft model that harbors a human BM-like 423 
niche in which we could recapitulate both the myelomonocytic and B-ALL phenotypes 424 
that are observed in MLL-AF9 pediatric patients. Compared to the murine environment 425 
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of NOD-SCID/NSG mice, a higher percentage of myeloid clones could be generated in 426 
the huBM-sc model. This observation reinforces the notion that the lineage fate of MLL-427 
AF9 LSCs is dictated primarily by microenvironmental cues and cell of origin rather than 428 
an instructive role of the fusion partner gene. While we could easily serially transplant 429 
huBM-sc derived B-ALL clones, 2nd engraftment of myeloid clones was more difficult to 430 
achieve. Possibly, the level of myeloid growth factors such as IL314, an important and 431 
species-specific growth factor for myeloid leukemias driven by MLL-AF9, are still too low 432 
in our huBM-sc model. Ongoing experiments include further improvement of the huBM-433 
sc model using MSCs that we have genetically engineered to express cytokines such as 434 
IL3 and TPO. On the other hand, Wei and colleagues reported that upon injection of CB 435 
CD34+ cells transduced with MLL-AF9 into NS-SGM3 mice only AML but not B-ALL 436 
developed, suggesting that these mice are now strongly biased towards myelopoiesis. 437 
Besides lentiviral models for MLL-AF9, we also showed that primary AML MLL-AF9 438 
derived from an adult patient could engraft efficiently in the huBM-sc, and it will be 439 
interesting to compare the human cytokine mice with our humanized niche scaffold 440 
model side-by-side in future experiments.  441 
We also find that primary CD34+ CML patient cells can efficiently engraft in this 442 
xenograft model, whereby stemness is much better preserved in the human 443 
environment as compared to the mouse environment. Furthermore, we describe that 444 
this humanized niche model also allows for BCR-ABL-driven myeloid and lymphoid 445 
disease, in contrast to the NOD-SCID/NSG mouse in which exclusively CD19+ B-ALL 446 
was observed upon transplantation of transduced CB CD34+ cells (current study and 16). 447 
Our previous studies in NSG mice showed that BCR-ABL as single hit was never 448 
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sufficient to induce leukemia in the context of a murine niche6, in line with data 449 
published by others.26Only when additional hits were provided, such as co-expression of 450 
BMI1, a serially transplantable CD19+ B-ALL could be induced.6 Possibly, BMI1 was 451 
required to bypass (oncogene-induced) senescence, and also in mouse models BMI1 452 
was shown to reprogram BCR-ABL+ lymphoid progenitors into B-ALL-initiating cells.27 In 453 
the huBM-sc xenograft model that we present here, transformation was achieved with 454 
both BCR-ABL-only expressing cells as well as with cells that expressed both BCR-ABL 455 
and BMI1. Apparently, exogenous BMI1 is not an absolute requirement to allow 456 
transformation of human CB CD34+ cells transduced with only BCR-ABL.  457 
Finally, striking differences were observed between transcriptomes of leukemic cells 458 
derived from murine BM niches versus leukemic cells derived from the huBM scaffold 459 
niches, including in genes associated with hypoxia signaling, mitochondria and 460 
metabolism. Within the top differentially expressed genes there was enrichment for cell 461 
cycle inhibitors, like CDKN1C/p57, and hypoxic signature-related genes in the 462 
humanized microenvironment, genes that have been shown to contribute to stemness 463 
of HSCs/LSCs.28-32 Also, we find that endogenous BMI1 was strongly upregulated in the 464 
human BM niche. Apparently, the human BM niche can provide for factors that induce 465 
BMI1 expression, possibly through activation of SALL4 or the Sonic Hedgehog pathway, 466 
which both have been shown to be able to induce BMI1 expression.33,34 In conclusion, 467 
we describe here a huBM-sc xenograft model in which the myeloid and lymphoid 468 
features of MLL-AF9 and BCR-ABL+ leukemias can be studied in detail, both using 469 
lenti/retroviral model systems as well as patient samples, in which the efficacy of novel 470 
drugs can be evaluated. 471 
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Figure legends 598 
Figure 1. Mouse versus human extrinsic cues dictate transformation potential in 599 
BCR-ABL/BMI1 and MLL-AF9-induced leukemia in humanized xenograft models. 600 
(a) Kaplan-Meier survival curves of BCR-ABL/BMI injected primary and secondary mice 601 
from mBM i.v. and huBM i.sc. models displaying the differences in kinetics of leukemia 602 
development. (b) Kaplan-Meier survival curves of CB MLL-AF9 injected primary and 603 
secondary mice from mBM i.v. and huBM i.sc. models displaying the differences in 604 
kinetics of leukemia development. (c-d) A summary of phenotypes observed in mBM i.v 605 
and huBM i.sc models for BCR-ABL and MLL-AF9. 606 
 607 
Figure 2. BCR-ABL can induce lymphoid and myeloid leukemia in a human niche 608 
xenotransplant model without exogenous BMI1. (a) Detailed FACS analyses of 609 
BCR-ABL positive cells from Scaffold 3 of Mouse 5 indicating positive surface marker 610 
expression for CD19, CD38 and also for CD33, CD15. (b) 16 weeks post-611 
transplantation a tumor was detected at the site of injection. (c) HE staining of B-ALL 612 
tumor scaffold demonstrating efficient bone formation. (d) B-ALL tumor scaffold section 613 
stained by immunohistochemistry for CD45 demonstrated engraftment of CD45+ human 614 
cells. CD45- cells were also observed suggesting the presence of endothelial cells 615 
forming a vascularized niche. (e) MGG staining confirmed the lymphoblastic phenotype 616 
of BCR-ABL single positive cells. (f) FACS analyses of BCR-ABL positive cells from 617 
Scaffold 1 and 3 of Mouse 1 indicating expression of GPA, CD71 and CD33 markers. 618 
The more reddish Scaffold 3 was also the most positive for GPA.  619 
 620 
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Figure 3. Increased incidence of myeloid leukemia on MLL-AF9 induction 621 
observed in huBM-sc as compared to NSG. (a) FACS analyses of MLL-AF9 cells 622 
from BM, Sc1 and Sc2 of ISC mouse 1. (b) Picture showing tumor initiated on the 623 
scaffolds for mouse 1. (c) B-ALL tumor scaffold 1 section stained by 624 
immunohistochemistry for CD45 demonstrated engraftment of CD45+ human cells. (d) 625 
HE staining of B-ALL tumor scaffold 1 demonstrating efficient bone formation. (e) FACS 626 
analyses of MLL-AF9 cells from BM, Sc1 and Sc2 of ISC mouse 6. (f-g) MGG staining 627 
of BM and Sc1 of ISC mouse 6 confirming the lymphoblastic phenotype (h) MGG 628 
staining of Sc2 of mouse 6 confirming the presence of lymphoid and myeloid cells.  629 
 630 
Figure 4. Molecular characterization of murine niche versus human niche derived 631 
cells. (a) Gene expression profile of BCR-ABL positive cells harvested from a primary 632 
huBM-sc m5 (Scaffold 3), 8 secondary huBM-sc scaffolds (from m5.1, m5.2 and m5.3) 633 
as well as BCR-ABL/BMI1 positive cells harvested from BM and spleen (2x) from 634 
primary i.v. injected mice. A supervised hierarchical clustering analyses of differentially 635 
expressed genes is shown (differentially expressed genes were determined by using a 636 
corrected p value<0.01 with Benjamini-Hochberg multiple testing correction, and >3 fold 637 
difference in expression levels, Supplementary Table S1). Primary and secondary 638 
huBM-sc. samples clustered together, away from all 3 primary i.v. injected samples. 639 
BMI1, CDKN1C/p57, and MYC were some of the interesting candidate genes 640 
upregulated in huBM-sc 1st and 2nd scaffold derived samples. (b) Gene Ontology (GO) 641 
analyses on genes up- or downregulated in huBM-sc (human) niche derived cells 642 
versus i.v. injected murine niche-derived samples (>3 fold in i.sc. versus i.v. samples, p-643 
29 
value of ≤ 0.01). (c) GSEA analyses on i.sc. versus i.v. samples. (d) GO terms of up 644 
regulated genes in huBM-sc 1st and 2nd scaffold derived samples. (e) Validation of 645 
Illumina data by real time PCR indicating expression of endogenous BMI1, p57 and 646 
MYC relative to the house-keeping gene RPL27. Experiments were performed in 647 
triplicate. 648 
 649 
Figure 5. Primary Blast Crisis (BC)-CML and AML MLL-AF9 cells can engraft in 650 
the huBM scaffold mouse model and induce a fatal myeloid leukemia within 16 651 
weeks post transplantation. (a) A myeloid BC-CML patient sample was injected in 3 652 
scaffolds and 1 scaffold was left uninjected in 3 different humanized mice. 1.5x105 653 
50,000 cells per scaffold were injected. (b) All 3 injected mice developed enlarged 654 
greenish tumors within 16 weeks post-transplantation. (c) Detailed FACS analyses of 655 
CD45+ engrafted cells derived from humanized scaffolds as well as from the murine BM. 656 
CD34 was higher expressed in cells retrieved from the human scaffold while CD15, 657 
CD11b and CD14 were higher expressed in cells derived from the murine BM. (d) MGG 658 
staining indicated a more immature phenotype of scaffold-harvested cells as compared 659 
to more differentiated cells from the murine BM (63X magnification). (e). Tumor growth 660 
of a scaffold injected with 1 × 106   primary MLL-AF9 AML patient cells.  (f). FACS 661 
phenotype of cells harvested from the scaffold displayed in g and from mouse 662 
compartments (PB, BM, Liver and Spleen). (g) MGG staining of cytospins of cells 663 
harvested from the scaffold displayed in e.  664 
 665 
Figure 6. I-BET1 efficacy using MLL-AF9 huBM-sc model. 666 
30 
 (a) Schematic representation of the experimental design. Control mice were injected 667 
with normal saline containing 1% (v/v) DMSO. Treated mice were injected with 500µM 668 
and 5mM I-BET151 (b) Tumor volumes measured by caliper during the course of the 669 
experiment. (c) Pictures depicting tumors originated on huBM-sc. Comparison between 670 
control group and 5mM I-BET151 treated group. (d) Total cell number of tumors tumors 671 
originated on huBM-sc in the three groups. 672 
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